Eupraxia Pharmaceuticals (TSE:EPRX) has released an update.
Eupraxia Pharmaceuticals has revealed promising results from their RESOLVE trial, showing that EP-104GI, a treatment for eosinophilic esophagitis, maintains efficacy up to 24 weeks and improves patient symptoms and histological outcomes at 12 weeks. Utilizing their proprietary DiffuSphere™ technology, the trial also reported a favorable safety profile across all doses, with potential for extending treatment intervals at higher doses.
For further insights into TSE:EPRX stock, check out TipRanks’ Stock Analysis page.
